← Tutti gli studi
Chetogenica e low-carb
The interpretation and effect of a low-carbohydrate diet in the management of type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.
Huntriss R, et al. · 2018
PubMed 29269890 ↗DOI: 10.1038/s41430-017-0019-4European journal of clinical nutrition
🌱 La lettura di LEO
📉 Lavora su: Stabilità nel tempo · lente Traiettoria · il corpo nel tempo
tocca anche ⚓ Peso del cibo💊 Terapia
Revisione sistematica e meta-analisi di RCT (18 studi, 2.204 persone; 15 su 18 ad alto rischio di bias)
La domandaQuando due studi dicono 'dieta a bassi carboidrati', stanno parlando della stessa cosa? E quanto del beneficio dipende dai farmaci tolti?
Cosa hanno trovatoDiciotto studi randomizzati per 2.204 adulti col diabete tipo 2, con l'intervento definito 'a bassi carboidrati' secondo il criterio di ciascun autore. Il primo risultato e' proprio questo: la DEFINIZIONE varia da studio a studio. Nelle meta-analisi a un anno (7 studi) la dieta a bassi carboidrati risultava favorita per emoglobina glicata (effetto stimato -0,28%; IC 95% da -0,53 a -0,02; p = 0,03), colesterolo HDL (+0,06 mmol/L; p < 0,00001), trigliceridi (-0,24 mmol/L; p < 0,0001) e pressione sistolica (-2,74 mmHg; p = 0,03). Nessuna differenza significativa su peso, colesterolo totale, LDL e pressione diastolica. Gli autori segnalano due cose: il gruppo a bassi carboidrati riduceva i farmaci per il diabete, e questo puo' aver ATTENUATO il beneficio osservato sulla glicata; e una dieta a bassissimi carboidrati (sotto 50 g al giorno) appare irrealistica in questa popolazione, mentre una sotto i 130 g al giorno risulta raggiungibile. Quindici studi su diciotto sono stati giudicati ad alto rischio di bias.
Cosa significa per teE' la nota metodologica che rende leggibile tutto il resto dell'asse, e contiene un paradosso utile: nel gruppo low-carb la glicata scende MENO di quanto potrebbe perche' nel frattempo si tolgono i farmaci. Chi guarda solo l'HbA1c vede un vantaggio piccolo e conclude che la dieta serve poco; chi guarda anche le scatolette di medicine vede un'altra storia. L'altra indicazione e' molto pratica: i 130 g al giorno sono un obiettivo che le persone reali riescono a tenere, i 50 g quasi nessuno. Se l'obiettivo e' la tenuta, la low-carb moderata batte la chetogenica pura non perche' sia piu' potente, ma perche' esiste ancora fra sei mesi.
Abstract (in lingua originale)
BACKGROUND/OBJECTIVES: Recently, the role of a low-carbohydrate diet in diabetes management has generated interest with claims being made regarding its superiority over the traditional high-carbohydrate, low-fat dietary approach. This systematic review and meta-analysis evaluated the interpretation and effect of a low-carbohydrate diet in the management of type 2 diabetes. SUBJECTS/METHODS: Randomised controlled trials were searched for which included adults with type 2 diabetes aged 18 years or more. The intervention was a low-carbohydrate diet as defined by the author compared to a control group of usual care. MEDLINE, EMBASE, CINAHL, Cochrane Central Register of Controlled Trials, ISRCTN, ProQuest and opengrey.eu were searched. Independent experts were contacted and reference lists of selected papers were checked. Results were analysed descriptively and meta-analyses were completed to include trials that presented data at 1 year. RESULTS: Eighteen studies (n = 2204) were eligible for inclusion within the systematic review. The definition of a low-carbohydrate diet varied. At trial end, the descriptive analysis suggested that the low-carbohydrate intervention arm (LCIA) may promote favourable outcomes in terms of HbA1c, triglycerides and HDL cholesterol. The LCIA demonstrated reduced requirements for diabetes medication, which may have reduced the observed benefit of dietary carbohydrate restriction on HbA1c. Seven studies provided data to be included in the meta-analyses at 1 year. The meta-analyses showed statistical significance in favour of the LCIA for HbA1c (estimated effect = -0.28%, 95% CI -0.53 to -0.02, p = 0.03; χ 2 = 13.15, df = 6, p = 0.03; I 2 = 54%), HDL cholesterol (estimated effect = 0.06 mmol/L, 95% CI 0.04-0.09, p < 0.00001; χ 2 = 6.05, df = 6, p = 0.42; I 2 = 1%), triglycerides (estimated effect = -0.24 mmol/L, 95% CI -0.35 to -0.13, p < 0.0001; χ 2 = 1.88, df = 6, p = 0.93; I 2 = 0%) and systolic blood pressure (estimated effect = -2.74 mmHg, 95% CI -5.27 to -0.20, p = 0.03; χ 2 = 10.54, df = 6, p = 0.10; I 2 = 43%). Meta-analyses for weight, total cholesterol, LDL cholesterol and diastolic blood pressure did not demonstrate a statistically significant difference between interventions. Dietary adherence was an issue in most studies. A very low-carbohydrate diet (<50 g/day) seems unrealistic in this population, however, a low-carbohydrate diet (<130 g/day) appears to be achievable. Improved clinical outcomes were observed in some studies as a result of achieving a low- or moderate-carbohydrate diet. Fifteen out of 18 studies were considered high risk of bias, with performance bias being a common issue. CONCLUSIONS: Reducing dietary carbohydrate may produce clinical improvements in the management of type 2 diabetes. Further research is needed to understand the true effect of dietary carbohydrate restriction on HbA1c independent of medication reduction and to address known issues with adherence to this dietary intervention. Clarity is needed regarding appropriate classification of a low-carbohydrate diet.
💬 Chiedi a LEO di spiegartelo
Come leggerlo: è uno studio scientifico peer-reviewed. Le evidenze aiutano a capire i trend, ma un singolo studio non è una prescrizione: parlane col tuo diabetologo prima di cambiare dieta o terapia.